<DOC>
	<DOCNO>NCT02597179</DOCNO>
	<brief_summary>The purpose study investigate analyse genomic profile patient breast cancer fail standard treatment , refractory young breast cancer .</brief_summary>
	<brief_title>Genome Sequencing Refractory Breast Cancer Molecular Targeted Therapy Young Breast Cancer</brief_title>
	<detailed_description>The hypothesis genomic profiling measure CancerSCAN , cfDNA , Whole exome sequencing ( WES ) , Whole transcriptome sequencing ( WTS ) , FACS ( Fluorescence-Activated Cell Sorting ) , cytokine immunologic signature analysis would helpful find tolerance chemotherapy innovate new therapeutic strategy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm breast cancer either metastatic young breast cancer ( ≤ 40 year age ) . 2 . HER2 positive patient fail HER2 target therapy include trastuzumab feasible biopsy site . 3 . Triple Negative Breast Cancer patient fail standard therapy feasible biopsy site . 4 . Hormone Receptor positive patient fail standard therapy feasible biopsy site . 5 . Age ≥ 21 year 6 . Written inform consent 1 . No feasible biopsy site 2 . No write inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>